By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received marketing approval from China’s National Medical Products Administration (NMPA) for ibrexafungerp, a novel antifungal drug for the treatment of vulvovaginal candidiasis (VVC) in adult and post-menarche females. This approval marks a significant milestone in the company’s expanding portfolio of antifungal therapies.
Drug Mechanism
Ibrexafungerp is the world’s first antifungal drug with a novel triterpenoid structure that selectively inhibits glycogen synthase. This unique mechanism of action provides broad-spectrum efficacy against resistant fungal strains, including those unresponsive to traditional azoles and echinocandins.
Clinical and Market Significance
The approval underscores ibrexafungerp’s potential to address significant unmet medical needs in the treatment of fungal infections. Preclinical and clinical studies have demonstrated its effectiveness in managing VVC, a common condition affecting a substantial patient population.-Fineline Info & Tech